Research Topics
| D E FariesSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Simple options for improving signal detection in antidepressant clinical trialsCraig H Mallinckrodt
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Psychopharmacol Bull 40:101-14. 2007..Researchers may be able to take advantage of these easy-to-implement methods while we wait for further improvements in other areas...
Analysis of treatment effectiveness in longitudinal observational dataDouglas Faries
Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
J Biopharm Stat 17:809-26. 2007..Marginal structural models are a promising approach to estimation of causal treatment effects in such data...
Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetesDouglas Faries
Eli Lilly and Company, Indianapolis, IN, USA Electronic address
Value Health 16:259-66. 2013..Further research to understand the operating characteristics of these methods in a variety of situations, however, remains...
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trialDouglas Faries
Eli Lilly and Company, Lilly Corporate Center, DC 5024, Indianapolis, IN 46285, USA
BMC Med Res Methodol 12:142. 2012....
The cost of relapse and the predictors of relapse in the treatment of schizophreniaHaya Ascher-Svanum
US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
BMC Psychiatry 10:2. 2010..To assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States...
Cost of antipsychotic polypharmacy in the treatment of schizophreniaBaojin Zhu
Eli Lilly and Company, Indianapolis, Indiana, USA
BMC Psychiatry 8:19. 2008..This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of the 3 most commonly prescribed atypical antipsychotics - olanzapine, quetiapine, or risperidone...
Predictors of switching antipsychotic medications in the treatment of schizophreniaAllen W Nyhuis
Eli Lilly and Company, Indianapolis, IN USA
BMC Psychiatry 10:75. 2010..To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia...
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaHaya Ascher-Svanum
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
BMC Psychiatry 6:8. 2006..This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index of medication effectiveness in the treatment of schizophrenia...
Evaluating dose response from flexible dose clinical trialsIlya Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis Indiana, USA
BMC Psychiatry 8:3. 2008..The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related...
Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patientsHaya Ascher-Svanum
Eli Lilly and Company, Indianapolis, IN, USA
BMC Psychiatry 9:46. 2009....
Involvement in the US criminal justice system and cost implications for persons treated for schizophreniaHaya Ascher-Svanum
Eli Lilly and Company, Indianapolis, IN, USA
BMC Psychiatry 10:11. 2010..This study assessed the prevalence of encounters with the criminal justice system, encounter types, and the estimated cost attributable to these encounters in the one-year treatment of persons with schizophrenia...
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophreniaDouglas E Faries
Eli Lilly and Co, Lilly Research Laboratories, Indianapolis, IN 46285, USA
Curr Med Res Opin 24:1399-405. 2008..Switching medications is common in the treatment of schizophrenia. This study examines the effectiveness of olanzapine therapy following a clinically warranted switch from risperidone during treatment of patients with schizophrenia...
Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study exampleDouglas E Faries
Lilly USA, LLC, Indianapolis, Indiana, USA
Cost Eff Resour Alloc 7:11. 2009..Given the importance of quality economic research on the cost of switching treatments, thorough sensitivity analyses should be performed to identify the impact of crisis events around the time of medication change...
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophreniaDouglas E Faries
US Statistics, Lilly USA, LLC, Indianapolis, IN, USA
BMC Psychiatry 9:54. 2009..The goal of this research was to assess the clinical and economic ramifications of switching antipsychotics during outpatient management of schizophrenia...
The responsiveness of the Hamilton Depression Rating ScaleD Faries
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Psychiatr Res 34:3-10. 2000..Effect sizes from each individual HAMD item will also be presented to help explain the differences in responsiveness between the scales...
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychoticsDouglas Faries
Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
BMC Psychiatry 5:26. 2005..This study assessed the annual rate and duration of antipsychotic monotherapy and its inverse, antipsychotic polypharmacy, among schizophrenia patients initiated on commonly used atypical antipsychotic medications...
The double-blind variable placebo lead-in period: results from two antidepressant clinical trialsD E Faries
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
J Clin Psychopharmacol 21:561-8. 2001..This resulted in an increased drug-placebo treatment difference in one of the two studies but had no effect on the treatment difference in the other study...
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trialSandra L Tunis
US Medical Division, Eli Lilly and Company, Indianapolis, IN 46285, USA
Value Health 9:77-89. 2006..029). CONCLUSIONS: Approaches that integrate costs, effectiveness, and treatment patterns are important for providing optimal information regarding the value of first-line antipsychotic options for schizophrenia...
Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophreniaH Ascher-Svanum
Lilly Corporate Center, DC 4133, Eli Lilly and Company, Indianapolis, IN 46285, USA
Eur Psychiatry 26:313-9. 2011..This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine...
An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophreniaSandra L Tunis
Health Economics and Outcomes Research, IMS Health, Noblesville, IN, USA
Curr Med Res Opin 23:97-104. 2007..The objective of this study was to examine the ability of selected variables to predict antipsychotic persistence among patients receiving olanzapine or risperidone as initial treatment...
ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrumentS Zhang
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Int J Methods Psychiatr Res 14:186-201. 2005..Overall, the data from this study support the use of the ADHD RS as a clinician-rated instrument for assessing the severity of ADHD symptoms in children and adolescents in Europe...
Costs of treating patients with schizophrenia who have illness-related crisis eventsBaojin Zhu
Eli Lilly and Company, Indianapolis, USA
BMC Psychiatry 8:72. 2008..This naturalistic prospective study assessed the association of recent crises with mental health treatment costs among persons receiving treatment for schizophrenia...
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled studyDavid Michelson
Lilly Research Laboratories, Indianapolis, IN 46285, USA
J Am Acad Child Adolesc Psychiatry 43:896-904. 2004..Attention-deficit/hyperactivity disorder (ADHD) is typically treated over extended periods; however, few placebo-controlled, long-term studies of efficacy have been reported...
Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorderXianchen Liu
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 4123, Indianapolis, IN 46285, USA
Int Clin Psychopharmacol 25:315-22. 2010..The findings suggest that patients initiated with a dose of 60 mg/day of duloxetine seem to be more adherent to and persistent with the medication than those initiated with less or more than 60 mg/day...
Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careHaya Ascher-Svanum
Eli Lilly and Co, Indianapolis, Ind, USA
J Clin Psychiatry 67:453-60. 2006....
Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophreniaHaya Ascher-Svanum
Eli Lilly and Company, Indianapolis, IN 46285, USA
Schizophr Bull 34:1163-71. 2008..This study assessed the predictive accuracy of early nonresponse to treatment and its clinical, functional, and economic ramifications in the naturalistic treatment of predominately chronic outpatients treated for schizophrenia...
Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectivesHaya Ascher-Svanum
Eli Lilly and Company, Indianapolis, IN 46285, USA
Curr Med Res Opin 26:2403-10. 2010..To identify reasons for discontinuation and continuation of antipsychotic medications in the treatment of schizophrenia from the patients' and their clinicians' perspectives...
Comparing time to onset of response in antidepressant clinical trials using the cure model and the Cramer-von Mises testR N Tamura
Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
Stat Med 19:2169-84. 2000..Results of the simulation study suggest that for common designs and sample sizes used in such trials, the statistic has reasonable size and power properties as long as censoring is moderate...
Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?Amy R Perwien
Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana, USA
J Child Adolesc Psychopharmacol 16:713-24. 2006..This study examines the long-term effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents with ADHD...
Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetineAmy R Perwien
Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
J Dev Behav Pediatr 25:264-71. 2004..Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD...
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorderJoseph Biederman
Massachusetts General Hospital, Boston, Massachusetts, USA
Pediatrics 110:e75. 2002..One patient from each of the atomoxetine and placebo groups discontinued the study as a result of an adverse event. CONCLUSION: Atomoxetine was found to be effective and well tolerated for the treatment of ADHD in school-age girls...
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorderThomas Spencer
Massachusetts General Hospital, Boston, USA
J Clin Psychiatry 63:1140-7. 2002..In addition, atomoxetine was found to be well tolerated...
The burden of depressive symptoms in the long-term treatment of patients with schizophreniaRobert R Conley
Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
Schizophr Res 90:186-97. 2007..To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia...
A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 yearJan K Buitelaar
University Medical Center St Radboud, Nijmegen, The Netherlands
Biol Psychiatry 61:694-9. 2007..The efficacy of atomoxetine in maintaining symptom response following 1 year of treatment was assessed in children and adolescents (n = 163) with DSM-IV defined attention-deficit/hyperactivity disorder (ADHD)...
Atomoxetine in the management of children with ADHD: effects on quality of life and school functioningRonald T Brown
Temple University, Department of Public Health, PA 19140, USA
Clin Pediatr (Phila) 45:819-27. 2006..The effects of atomoxetine on other functional outcomes including academic performance and health-related outcomes are of interest, albeit less compelling for this particular investigation, than for the effects on overt symptom display...
Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance useDavid A Smelson
J Clin Psychopharmacol 26:666-7. 2006
Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL)Louis S Matza
Center for Health Outcomes Research at UBC, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
Qual Life Res 16:1511-20. 2007....
Abuse liability assessment of atomoxetine in a drug-abusing populationDonald R Jasinski
Johns Hopkins School of Medicine, Center for Chemical Dependence, 4940 Eastern Avenue, Baltimore, MD 21224, USA
Drug Alcohol Depend 95:140-6. 2008..This study assessed the abuse potential of atomoxetine in stimulant-preferring drug abusers compared to methylphenidate and phentermine as positive controls and desipramine and placebo as negative controls...
